Pirprofen in the treatment of migraine and episodic headache attacks: a placebo-controlled crossover clinical trial.
A double-blind, within patient, randomized study to compare the efficacy and tolerability of acute rectal administration of 600 mg pirprofen capsules with matched placebo was carried out in 40 out-patients. They were divided into two groups of 20 patients each according to diagnosis of episodic headache or common or classic migraine. Treatment was given once during each of two consecutive attacks according to a crossover design. None of the patients was withdrawn after randomization. There was a statistically significant difference in favour of pirprofen as regards the preferences expressed by patients at the end of the trial: 34 patients preferred pirprofen, two preferred placebo and four patients had no preference. Pirprofen significantly reduced the duration of headache attack and associated symptoms, but not the peak of pain intensity. Tolerability of the drug was good.
Guidotti
M
M
Headache and Migraine Ambulatory, Sanrocco Centre, Como, Italy.
Zanasi
S
S
Garagiola
U
U
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006261:Headache / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D010666:Phenylpropionates / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D011897:Random Allocation
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010666:Phenylpropionates; D010919:Placebos; C008924:pirprofen